Morons and peons, assistants and deputies

by Skip

Heh!  From Stix Blog:

Discovery-New Element

New Element Research has led to the discovery of the heaviest element yet known to science. The new element, Governmentium (Gv),has one neuron, 25 assistant neurons, 88 deputy neurons, and 198 assistant deputyneurons, giving it an atomic mass of 312.

These 312 particles are held together by forces called morons,which are surrounded by vast quantities of lepton-like particles called peons. Since Governmentium has no electrons, it is inert; however, it can be detected, because it impedes every reaction with which it comes into contact. A minute amount of Governmentium can cause a reaction that would normally take less than a second can take from four days to four years to complete.

Governmentium has a normal half-life of 2-6 years; it does not decay, but instead undergoes a reorganization in which a portion of the assistant neurons and deputy neurons exchange places. In fact, Governmentium’s mass will actually increase over time, since each reorganization will cause more morons to become neurons, forming isodopes.This characteristic of moron promotion leads some scientists to believe that Governmentium is formed whenever morons reach a critical concentration. This hypothetical quantity is referred to as critical morass.

When catalyzed with money, Governmentium becomes Administratium, an element that radiates just as much energy as Governmentium since it has half as many peons but twice as many morons.

Like it? Share it!

Leave a Comment

  • http://www.granitegrok.com Doug

    An oldie, but a goodie!

  • akhil

    hello,
    Jubilant Biosys Ltd has signed a research collaboration agreement with, AstraZeneca under the shared risk-reward collaboration, which will initially focus on the neuroscience area. Jubilant Biosys, a subsidiary of Jubilant Organosys Ltd, focusses on delivering drug candidates into the international pharmaceutical company’s pre-clinical pipeline and aims to deliver a steady stream of discovery programmes to AstraZeneca. The deal lifted Jubilant’s shares by over 13.3 per cent to Rs 133 in the Mumbai market.
    AstraZeneca will own the compounds developed under the collaboration with worldwide development and commercialisation rights, while funding Jubilant’s research for the initial five-year period. AstraZeneca will also pay Jubilant success-based development milestones, as well as royalties based on successful global commercialisation of any of the compounds. The deal will have a revenue implication between $165 million and $275 million provided the programmes are 100 per cent successful.
    =========================
    akhil
    ==========================
    Alaska Drug Rehab Centers and Programs-

Previous post:

Next post: